C Annerén1, M Welsh. 1. Department of Medical Cell Biology, Uppsala University, Sweden. cecilia.anneren@medcellbiol.uu.se
Abstract
BACKGROUND: The loss of beta cells in type 1 diabetes may involve protein kinases because they control cell growth, differentiation, and survival. Previous studies have revealed that GTK, a Src-like protein tyrosine kinase expressed in beta cells (also named Bsk/Iyk), regulates multiple responses including growth and survival of rat insulinoma cells (RINm5F) and differentiation of neuronal PC12 cells. In the present study, we have generated a transgenic mouse expressing a kinase active GTK mutant (GTK-Y504F) under the control of the rat insulin I promoter to establish a role of GTK in beta cells. MATERIALS AND METHODS: Control and GTK-transgenic CBA mice were used for determination of in vivo glucose tolerance and the relative insulin-positive area. Isolated islets from both groups were cultured in the absence and presence of cytokines and insulin secretion, viability and protein expression were assessed. RESULTS: The beta-cell mass of GTK-transgenic mice was increased as a consequence of a larger pancreas and an increased relative beta-cell area. Islets isolated from the transgenic animals exhibited an enhanced glucose-induced insulin release and reduced viability in response to cytokines that could not be explained by higher levels of nitric oxide (NO) compared with control islets. Extracellular signal-regulated kinase (ERK) 1/2, p38 mitogen-activated protein kinase (MAPK), c-Jun NH2-terminal kinase (JNK), and Akt were all activated by cytokines, but GTK-transgenic islets contained higher basal levels of phosphorylated ERK1/2 and lower basal levels of phosphorylated p38 compared with the control islets. The total amount of activated MAPKs was, however, higher in the cytokine-stimulated transgenic islets compared with the control islets due to increased levels of phospho-ERK1/2. Moreover, the proline-rich tyrosine kinase (PYK) 2 (also named RAFTK/CAK beta/CADTK) levels were elevated in response to a 24-hr exposure to cytokines in control islets but not in the GTK-transgenic islets. CONCLUSIONS: These results suggest that although GTK increases the beta-cell mass, it also enhances islet cell death in response to cytokines and may thus be involved in the beta-cell damage in type 1 diabetes.
BACKGROUND: The loss of beta cells in type 1 diabetes may involve protein kinases because they control cell growth, differentiation, and survival. Previous studies have revealed that GTK, a Src-like protein tyrosine kinase expressed in beta cells (also named Bsk/Iyk), regulates multiple responses including growth and survival of ratinsulinoma cells (RINm5F) and differentiation of neuronal PC12 cells. In the present study, we have generated a transgenicmouse expressing a kinase active GTK mutant (GTK-Y504F) under the control of the rat insulin I promoter to establish a role of GTK in beta cells. MATERIALS AND METHODS: Control and GTK-transgenic CBA mice were used for determination of in vivo glucose tolerance and the relative insulin-positive area. Isolated islets from both groups were cultured in the absence and presence of cytokines and insulin secretion, viability and protein expression were assessed. RESULTS: The beta-cell mass of GTK-transgenic mice was increased as a consequence of a larger pancreas and an increased relative beta-cell area. Islets isolated from the transgenic animals exhibited an enhanced glucose-induced insulin release and reduced viability in response to cytokines that could not be explained by higher levels of nitric oxide (NO) compared with control islets. Extracellular signal-regulated kinase (ERK) 1/2, p38 mitogen-activated protein kinase (MAPK), c-Jun NH2-terminal kinase (JNK), and Akt were all activated by cytokines, but GTK-transgenic islets contained higher basal levels of phosphorylated ERK1/2 and lower basal levels of phosphorylated p38 compared with the control islets. The total amount of activated MAPKs was, however, higher in the cytokine-stimulated transgenic islets compared with the control islets due to increased levels of phospho-ERK1/2. Moreover, the proline-rich tyrosine kinase (PYK) 2 (also named RAFTK/CAK beta/CADTK) levels were elevated in response to a 24-hr exposure to cytokines in control islets but not in the GTK-transgenic islets. CONCLUSIONS: These results suggest that although GTK increases the beta-cell mass, it also enhances islet cell death in response to cytokines and may thus be involved in the beta-cell damage in type 1 diabetes.
Authors: Mi Young Jung; Bum Shik Kim; Youn Jung Kim; In Song Koh; Joo-Ho Chung Journal: Korean J Physiol Pharmacol Date: 2008-04-30 Impact factor: 2.016
Authors: Michael Welsh; Charlotte Welsh; Maria Ekman; Johan Dixelius; Robert Hägerkvist; Cecilia Annerén; Björn Akerblom; Siavosh Mahboobi; Subhashini Chandrasekharan; Edison T Liu Journal: Biochem J Date: 2004-08-15 Impact factor: 3.857
Authors: Mariana Lizbeth Rodríguez-López; José Jaime Martínez-Magaña; David Ruiz-Ramos; Ana Rosa García; Laura Gonzalez; Carlos Alfonso Tovilla-Zarate; Emmanuel Sarmiento; Isela Esther Juárez-Rojop; Humberto Nicolini; Thelma Beatriz Gonzalez-Castro; Alma Delia Genis-Mendoza Journal: Nutrients Date: 2021-04-22 Impact factor: 5.717
Authors: Emanuele Bosi; Lorella Marselli; Carmela De Luca; Mara Suleiman; Marta Tesi; Mark Ibberson; Decio L Eizirik; Miriam Cnop; Piero Marchetti Journal: NAR Genom Bioinform Date: 2020-11-20
Authors: Justin F Creeden; Khaled Alganem; Ali S Imami; Nicholas D Henkel; F Charles Brunicardi; Shi-He Liu; Rammohan Shukla; Tushar Tomar; Faris Naji; Robert E McCullumsmith Journal: Int J Mol Sci Date: 2020-11-21 Impact factor: 5.923